Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more
Gan & Lee Pharmaceuticals Co Ltd (603087) - Total Liabilities
Latest total liabilities as of September 2025: CN¥860.37 Million CNY
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) has total liabilities worth CN¥860.37 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gan & Lee Pharmaceuticals Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gan & Lee Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Gan & Lee Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IPCA Laboratories Limited
NSE:IPCALAB
|
India | ₹33.97 Billion |
|
Vodacom Group Ltd PK
PINK:VDMCY
|
USA | $146.48 Billion |
|
Rubis SCA
PA:RUI
|
France | €3.62 Billion |
|
Cembra Money Bank AG
PINK:CMBNF
|
USA | $6.60 Billion |
|
Galp Energa
PINK:GLPEY
|
USA | $10.12 Billion |
|
Konecranes ABP
LSE:0MET
|
UK | €2.49 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
USA | $152.54 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Gan & Lee Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gan & Lee Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gan & Lee Pharmaceuticals Co Ltd (2013–2024)
The table below shows the annual total liabilities of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥988.45 Million | +1.64% |
| 2023-12-31 | CN¥972.52 Million | -4.77% |
| 2022-12-31 | CN¥1.02 Billion | +48.87% |
| 2021-12-31 | CN¥686.02 Million | +20.55% |
| 2020-12-31 | CN¥569.09 Million | +2.38% |
| 2019-12-31 | CN¥555.88 Million | +31.05% |
| 2018-12-31 | CN¥424.18 Million | +3.97% |
| 2017-12-31 | CN¥408.00 Million | +17.22% |
| 2016-12-31 | CN¥348.06 Million | +6.96% |
| 2015-12-31 | CN¥325.41 Million | +98.20% |
| 2014-12-31 | CN¥164.18 Million | +65.29% |
| 2013-12-31 | CN¥99.33 Million | -- |